GoKawiilStudy details TRAM's role in Myddosome signaling independent of Toll-like receptors
Researchers describe laboratory methods used to study TRAM (Ticam2), a signaling adaptor, showing it can promote myddosome formation without direct involvement of Toll-like receptors. The work used immortalized and primary bone-marrow-derived macrophages from wild-type and Ticam2-knockout mice, alongside HEK293T cells, treated with bacterial components such as LPS, LTA and Pam2CSK4 to probe the pathway.
GoKawiil's interpretation of the reporting above, not reported fact.
This research could refine scientific understanding of innate immune signaling pathways, potentially identifying new points for therapeutic intervention in inflammatory or infectious disease research. Because the excerpt is primarily a methods description, the broader implications depend on results not detailed here, so any clinical relevance remains speculative at this stage.
- The study examines TRAM (Ticam2) as a mediator of myddosome signaling separate from Toll-like receptor engagement.
- Experiments relied on macrophages derived from wild-type and Ticam2-deficient mice alongside HEK293T cell lines.
- Materials and cell lines used are stated to be available from the corresponding authors upon request.
Source: nature.com — Fisch, 2026-09-23
Published there as: “TRAM promotes Toll-like-receptor-free myddosome signal transduction”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.